Table 1: Characteristics of the included studies.

AuthorYearJournalDrugTime to evaluatePrimary endpointGroupTotalMale, (%)Age (mean age)Duration of psoriasis (years)Involved body surface area (%)Baseline PASI score

Papp (AMAGINE-1)2016BJDBrodalumab12PASI 75210 mg222161 (73)
sPGA 0/1140 mg219162 (74)
Placebo220161 (73)

Lebwohl (AMAGINE-2)2015NEJMBrodalumab12PASI 75210 mg612421 (69)
sPGA 0/1140 mg610413 (68)
PASI 100Ustekinumab300205 (68)
Placebo309219 (71)

Lebwohl (AMAGINE-3)2015NEJMBrodalumab12PASI 75210 mg624431 (69)
sPGA 0/1140 mg629437 (70)
PASI 100Ustekinumab313212 (68)
Placebo315208 (66)

Papp2012NEJMBrodalumab12PASI 75210 mg3928 (72)
PASI 100140 mg3922 (56)
Placebo4230 (71)

Nakagawa2015JDSBrodalumab12PASI 75210 mg3729 (78.4)
PASI 100140 mg3730 (81.1)
sPGA 0/1Placebo3827 (71.1)

Rich2012BJDSecukinumab12PASI 75150 mg133105 (78.9)
Placebo6744 (65.7)

Paul (JUNCTURE)2015JEADVSecukinumab12PASI 75300 mg6046 (76.7)
IGA 0/1150 mg6141 (67.2)
Placebo6138 (62.3)

Langley (ERASURE)2014NEJMSecukinumab12PASI 75300 mg245169 (69.0)
IGA 0/1150 mg245168 (68.6)
Placebo248172 (69.4)

Langley (FIXTURE)2014NEJMSecukinumab12PASI 75300 mg327224 (68.5)
IGA 0/1150 mg327236 (72.2)
Placebo326237 (72.7)

Blauvelt (FEATURE)2015BJDSecukinumab12PASI 75300 mg5938 (64.4)
IGA 0/1150 mg5940 (67.8)
Placebo5939 (66.1)

Gordon (UNCOVER-1)2016NEJMIxekizumab12PASI 7580 mg Q4W432289 (66.9)
sPGA 0/180 mg Q2W433291 (67.2)
Placebo431303 (70.3)

Griffiths (UNCOVER-2)2015LancetIxekizumab12PASI 7580 mg Q4W347244 (70.3)
sPGA 0/180 mg Q2W351221 (63.0)
Placebo168120 (71.4)

Griffiths (UNCOVER-3)2015LancetIxekizumab12PASI 7580 mg Q4W386258 (66.8)
sPGA 0/180 mg Q2W385254 (66.0)
Placebo193137 (71.0)

IGARASHI2012JDUstekinumab12PASI 7545 mg6453 (82.8)45
90 mg6247 (75.8)44
Placebo3226 (83.9)49

Leonardi (PHOENIX 1)2008LancetUstekinumab12PASI 7545 mg255175 (68·6)44.819.727.220.5
90 mg256173 (67·6)46.219.625.219.7
Placebo255183 (71·8)44.820.427.720.4

Papp (PHOENIX 2)2008LancetUstekinumab12PASI 7545 mg409283 (69·2)45.119.325.919.4
90 mg411274 (66·7)46.620.327.120.1
Placebo410283 (69·0)47.020.826.119.4

Tsai (PEARL)2011JDSUstekinumab12PASI 7545 mg6150 (82.0)
Placebo6053 (88.3)

Zhu (LOTUS)2013JDDUstekinumab12PASI 7545 mg160125 (78.1)
Placebo162123 (75.9)

Krueger2007NEJMUstekinumab12PASI 7545 mg6439 (61)
90 mg6452 (81)
Placebo6446 (72)

Blauvelt (VOYAGE 1)2017JAADGuselkumab16IGA 0/1100 mg329240 (72.9)
PASI 90Placebo174119 (68.4)

Reich (VOYAGE 2)2017JAADGuselkumab16IGA 0/1100 mg496349 (70.4)
PASI 90Placebo248173 (69.8)

Gordon2015NEJMGuselkumab16PGA 0/150 mg4228 (67)43192519
100 mg4231 (74)42182421
Placebo4228 (67)46.5182822

OHTSUKI2017JDGuselkumab16IGA 0/150 mg6544 (67.7)50.115.2538.025.60
PASI 90100 mg6347 (74.6)47.814.3937.926.73
Placebo6454 (84.4)48.313.6633.625.92

Papp2015BJDTildrakizumab16PASI 75100 mg8976 (85)NRNRNR
200 mg8665 (76)NRNRNR
Placebo4638 (83)NRNRNR

Reich (reSURFACE 1)2017LancetTildrakizumab12PASI 75100 mg309207 (67)46.4NR29.720.0
PGA 0/1200 mg308226 (73)46.9NR30.920.7
Placebo155100 (65)47.9NR29.619.3

Reich (reSURFACE 2)2017LancetTildrakizumab12PASI 75100 mg307220 (72)44.6NR34.220.5
PGA 0/1200 mg314225 (72)44.6NR31.819.8
Placebo313222 (71)45.8NR31.620.2

Gordon (UltIMMa-1)2018LancetRisankizumab16PASI 90150 mg304212 (70)48.3NR26.220.6
sPGA 0/1Ustekinumab10070 (70)46.5NR25.220.1
Placebo10279 (77)49.3NR27.920.5

Gordon (UltIMMa-1)2018LancetRisankizumab16PASI 90150 mg294203 (69)46.2NR26.220.5
sPGA 0/1Ustekinumab9966 (67)48.6NR20.918.2
Placebo9867 (68)46.3NR23.918.9

Data are presented as the numbers (%) or the . PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 90: the percentages of patients with a 90% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported.